Highlight

1. Dual inhibitor of XO / URAT1, Orally-available，inhibitory activity of URAT1 is better than that of benzbromarone.

1) Xanthine Oxidase (XO) Inhibitor

Xanthine oxidase (XO) is a critical enzyme in the metabolism of purines to uric acid. Effective urate lowering via xanthine oxidase inhibition therapy is associated with a high risk of gout flares at the start of therapy.

2) Urate transporter 1 (URAT1) Inhibitor

Urate transporter 1 (URAT1) is a major protein involved in uric acid reabsorption (about 90%). URAT1 inhibitors are thought to be a highly effective and promising class of uricosuric agents for treating hyperuricemia.

2. Good efficacy and safety in preclinical study.

1) No toxicity observed in preclinical study.

2) Therapeutic effect in black-capped monkeys:

The results of in vivo efficacy experiments showed that：

Asset dose-dependently increases the amount of xanthine and hypoxanthine in blood, and inhibits XO activity.

Asset dose-dependently promotes renal uric acid excretion and inhibits URAT1 activity.

Research progress

1). Phase 1 trial in China;

2). Patent has been granted in both CN and US;

3). Decline of uric acid concentration was shown in black-capped monkeys.